Pressure BioSciences, Inc. (PBIO)
Chart Events
Performance Outlook
| Previous Close | 2.4800 |
| Open | 2.5000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.4200 - 2.5600 |
| 52 Week Range | 1.2900 - 4.9800 |
| Volume | 7,776 |
| Avg. Volume | 66,356 |
| Market Cap | 12.612M |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.2730 |
| Earnings Date | Nov 17, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga
Pressure BioSciences Partners with Academic and Industry Leaders to Revolutionize Food, Wellness and Biomedical Spaces
Image Provided By Pixabay Pressure BioSciences, Inc. (OTCQB: PBIO), the pioneer behind innovative, broadly applicable pressure-based technologies, has been aggressively pursuing strategic partnerships with academic and industry leaders, including Ohio State University and a range of biopharmaceutical and biotechnology companies, from recent start-ups to time-honored multibillion-dollar global entities. Through these partnerships, Pressure BioSciences (PBI) hopes to roll out its pressure-based te
- Benzinga
Pressure BioSciences, Inc. Reports Escalating Quarterly Revenue, Major Progress in Key Platform Technologies, and Formation of Eco-Friendly Agrochem Subsidiary that Already Posted Over $1 Million in Orders
Image Provided By Pexels Pressure BioSciences, Inc (OTCQB: PBIO), a leading developer of powerful pressure-based systems with applications across dozens of industries, recently reported its 2nd quarter results for 2021. With 127% revenue growth, a 51% decrease in operating loss and significant progress in many areas of operations, the quarter ending June 30 continued the company’s trend of strong quarter over quarter growth and provided reason for optimism about the 2nd half of 2021. Here are so
- Benzinga
Pressure BioSciences Reports Strong 2nd Quarter Financial and Business Results; Looks Forward to an Even Stronger 2nd Half of 2021
Image Provided By Pixabay Pressure BioSciences, Inc (OTCQB: PBIO) has enjoyed a near record-breaking first half of 2021, reporting the second-highest revenue growth ever, driven by the company’s aggressive growth plan. As Pressure BioSciences (PBI) works toward its goal of uplisting to NASDAQ or NYSE by the end of the year, its strong 2nd quarter results suggest that the company is well on its way toward achieving that goal. As PBI enters its 3rd quarter, here’s what it’s achieved so far and wha
